Tag: Harbour BioMed

Tumor necrosis factor

Click the tags to see associated articles and topics

View Article Details

Harbour BioMed Announces Dosing of First Patient in Phase I Clinical Study of its Next-Generation ...

Added to Collection on: 2021-03-22 00:22:30

Tags for this article:

Programmed cell death protein 1

Click the tags to see associated articles and topics

View Article Details

Harbour BioMed Announces Dosing of First Patient in Australia for Phase Ib/IIa Clinical Study of its ...

Added to Collection on: 2021-05-11 09:56:15

Tags for this article:

Dana–Farber Cancer Institute

Click the tags to see associated articles and topics

View Article Details

Harbour BioMed and Dana-Farber Cancer Institute Collaborate to Advance Novel Biotherapies for ...

Added to Collection on: 2021-06-16 04:41:15

Tags for this article:

Chimeric antigen receptor T cell

Bispecific monoclonal antibody

Biopharmaceutical

Programmed cell death protein 1

Click the tags to see associated articles and topics

View Article Details

Harbour BioMed Announces Dosing of First Patient of Next-Generation Anti-CTLA-4 Antibody in ...

Added to Collection on: 2021-06-17 07:41:15

Tags for this article:

Monoclonal antibody

Non-small-cell lung carcinoma

Thymic stromal lymphopoietin

Click the tags to see associated articles and topics

View Article Details

Harbour BioMed Announces Submission of IND Application for HBM9378/SKB378 in the ...

Added to Collection on: 2024-11-09 22:32:16

Tags for this article:

Immunology

Bispecific monoclonal antibody

Monoclonal antibody

Biopharmaceutical

Contract research organizations

Click the tags to see associated articles and topics

View Article Details

Harbour BioMed Announces Business Progress and Update - Placera

Added to Collection on: 2025-02-14 16:11:12

Tags for this article:

Click the tags to see associated articles and topics

View Article Details

Harbour BioMed Enters into Global Strategic Collaboration with AstraZeneca to ... - The Manila Times

Added to Collection on: 2025-03-21 11:50:01

Tags for this article:

Södertälje Municipality

Oxford–AstraZeneca COVID-19 vaccine

Biopharmaceutical

Bispecific monoclonal antibody

Chronic lower respiratory diseases

Click the tags to see associated articles and topics

View Article Details

HBM9378/WIN378, a Long-Acting, Fully Human Anti-TSLP Antibody, Enters Global Phase 2 ...

Added to Collection on: 2025-07-23 12:40:04

Tags for this article:

Immunology

Biotechnology

Glycoproteins

Cytokines

Thymic stromal lymphopoietin

Asthma